Items where authors include "Babu, S."

Article

Babu, S. orcid.org/0009-0007-1490-419X, Heidrich, E. orcid.org/0000-0001-7964-4156, Speight, V. orcid.org/0000-0001-7780-7863 et al. (5 more authors) (2026) Resistome characterisation from catchment to effluent in a treatment plant without hospital inputs: implications for AMR monitoring. Journal of Water and Health. jwh2026210. ISSN 1477-8920

Miller, T.M., Cudkowicz, M.E., Shaw, P.J. et al. (428 more authors) (2025) Long-term tofersen in SOD1 amyotrophic lateral sclerosis. JAMA Neurology, 83 (2). ISSN 2168-6149

Lovett, A., Chary, S., Babu, S. et al. (15 more authors) (2025) Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis. Muscle & Nerve, 71 (6). pp. 1006-1015. ISSN 0148-639X

van den Berg, L.H., Rothstein, J.D., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (26 more authors) (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology, 23 (9). pp. 901-912. ISSN 1474-4422

Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793

Dewan, R. orcid.org/0000-0002-7611-7032, Chia, R. orcid.org/0000-0002-4709-7423, Ding, J. et al. (469 more authors) (2021) Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron, 109 (3). 448-460.e4. ISSN 0896-6273